Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy

被引:32
|
作者
Sisti, Eleonora [1 ,2 ]
Coco, Barbara [3 ]
Menconi, Francesca [1 ,2 ]
Leo, Marenza [1 ,2 ]
Rocchi, Roberto [1 ,2 ]
Latrofa, Francesco [1 ,2 ]
Profilo, Maria Antonietta [1 ,2 ]
Mazzi, Barbara [1 ,2 ]
Vitti, Paolo [1 ,2 ]
Marcocci, Claudio [1 ,2 ]
Brunetto, Maurizia [3 ]
Marino, Michele [1 ,2 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Endocrinol Units, I-56124 Pisa, Italy
[2] Univ Hosp Pisa, I-56124 Pisa, Italy
[3] Univ Hosp Pisa, Hepatol Unit, Pisa, Italy
关键词
AUTOIMMUNE HEPATITIS; METHYLPREDNISOLONE; OPHTHALMOPATHY; MANAGEMENT; PATIENT; DISEASE;
D O I
10.1089/thy.2015.0061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: High-dose intravenous glucocorticoid (ivGC) pulse therapy, which is commonly used for Graves' orbitopathy (GO), has been associated with acute liver damage (ALD), resulting in a fatal outcome in a few cases. No certain risk factors for ALD have been established. Consequently, a large retrospective cohort study was performed. Methods: The relationship between ALD and several potential risk factors was assessed in 1076 consecutive patients with GO given ivGC. ALD was defined as an increase of alanine aminotransferase 300IU/L. Results: Fourteen cases of ALD were recorded, resulting in a morbidity of 1.3%. Thirteen patients recovered and one died, resulting in a mortality of 0.09%. There was a significant, positive correlation of ALD with age and methylprednisolone acetate (MPA) cumulative dose, and ALD was more common (relative risk [RR]=2.8; p=0.05) in patients aged 53 years (9/420; 2.14%) than in those aged <53 years (5/656; 0.76%). In patients aged 53 years, there was a significant positive correlation of ALD with MPA cumulative dose, and with MPA dose per infusion. Thus, the frequency of ALD in this age group was greater (RR=3.48; p=0.04) in patients with a MPA dose per infusion 0.7g (5/111, 4.5% vs. 4/308, 1.29%). Regardless of age, no cases of ALD were observed for MPA doses per infusion <0.57g. Conclusions: Age and MPA dose are significant risk factors for ALD, with the following practical implications. First, the total MPA cumulative dose should not exceed 8.5g (the average dose in patients without ALD). Second, in patients aged 53 years, selection and observation should be quite strict. However, being aged 53 years should not be seen as an absolute contraindication to ivGC, especially in patients with severe GO, considering that the risk of ALD, although statistically significant, was relatively low. Third, the MPA dose should not exceed 0.57g per infusion, a measure to be applied regardless of age.
引用
收藏
页码:846 / 850
页数:5
相关论文
共 50 条
  • [31] Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy
    Miskiewicz, Piotr
    Milczarek-Banach, Justyna
    Bednarczuk, Tomasz
    Opolski, Grzegorz
    Glowczynska, Renata
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (10)
  • [32] New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy
    Gursoy, Alptekin
    Cesur, Mustafa
    Erdogan, Murat Faik
    Corapcioglu, Demet
    Kamel, Nuri
    ENDOCRINE, 2006, 29 (03) : 513 - 516
  • [33] New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy
    Alptekin Gursoy
    Mustafa Cesur
    Murat Faik Erdogan
    Demet Çorapcioglu
    Nuri Kamel
    Endocrine, 2006, 29 : 513 - 516
  • [34] Radioiodine therapy and thyroid-associated orbitopathy: risk factors and preventive effects of glucocorticoids
    Dietlein, M
    Dederichs, B
    Weigand, A
    Schicha, H
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 : S190 - S194
  • [35] High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy
    Tagami, T
    Tanaka, K
    Sugawa, H
    Nakamura, H
    Miyoshi, Y
    Mori, T
    Nakao, K
    ENDOCRINE JOURNAL, 1996, 43 (06) : 689 - 699
  • [36] ASEPTIC-MENINGITIS ASSOCIATED WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN THERAPY - FREQUENCY AND RISK-FACTORS
    SEKUL, EA
    CUPLER, EJ
    DALAKAS, MC
    ANNALS OF INTERNAL MEDICINE, 1994, 121 (04) : 259 - 262
  • [37] Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy
    Ueda-Sakane, Yoriko
    Kanamoto, Naotetsu
    Fushimi, Yasutaka
    Tanaka-Mizuno, Sachiko
    Yasuno, Shinji
    Miura, Masako
    Sone, Masakatsu
    Yasoda, Akihiro
    Okada, Tomohisa
    Togashi, Kaori
    Nakao, Kazuwa
    Inagaki, Nobuya
    ENDOCRINE JOURNAL, 2016, 63 (08) : 703 - 714
  • [38] Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy
    Ohtsuka, K
    Sato, A
    Kawaguchi, S
    Hashimoto, M
    Suzuki, Y
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2002, 46 (05) : 563 - 567
  • [39] Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves’ orbitopathy: a small prospective pilot study
    S. Censi
    J. Manso
    G. Pandolfo
    G. Franceschet
    E. Cavedon
    Y. H. Zhu
    S. Carducci
    W. Gomiero
    M. Plebani
    M. Zaninotto
    S. Watutantrige-Fernando
    C. Mian
    V. Camozzi
    Journal of Endocrinological Investigation, 2019, 42 : 859 - 865
  • [40] Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves' orbitopathy: a small prospective pilot study
    Censi, S.
    Manso, J.
    Pandolfo, G.
    Franceschet, G.
    Cavedon, E.
    Zhu, Y. H.
    Carducci, S.
    Gomiero, W.
    Plebani, M.
    Zaninotto, M.
    Watutantrige-Fernando, S.
    Mian, C.
    Camozzi, V.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (07) : 859 - 865